Compare VRME & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRME | MBAI |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | Israel |
| Employees | 30 | 85 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.3M |
| IPO Year | N/A | N/A |
| Metric | VRME | MBAI |
|---|---|---|
| Price | $0.63 | $1.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 71.2K | 61.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $1.29 |
| 52 Week High | $1.51 | $3.92 |
| Indicator | VRME | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 31.00 | 44.55 |
| Support Level | N/A | $1.30 |
| Resistance Level | $0.93 | $1.83 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 30.43 |
VerifyMe Inc is a logistics company that specializes in time and temperature-sensitive products, as well as providing brand protection and enhancement solutions. The company operates through two reportable business segments: Precision Logistics offers a value-added service provider for time and temperature-sensitive parcel management. Using a proprietary IT platform, it provides real-time information and analysis to mitigate supply chain flow interruption, delivering last-mile resolution for key markets, including the perishable healthcare and food industries; and the Authentication segment specializes in anti-counterfeit and brand protection. The Precision Logistics segment derives the majority of the revenue.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.